The Medicines Management Programme has identified best-value medicines for a number of medicines, including:
Filgrastim
Best-value biological medicines: Filgrastim
The Medicines Management Programme (MMP) has identified best-value biological (BVB) medicines for medicinal products containing filgrastim on the High Tech Arrangement.
The MMP recommends the following as BVB medicines for filgrastim on the High Tech Arrangement:
- Accofil® (Accord Healthcare Ireland Limited)
- Tevagrastim® (Teva Pharmaceuticals Ireland)
A copy of the MMP Evaluation Report is available below.
Clinicians should give due consideration to prescribing a BVB medicine when issuing a prescription for filgrastim on the High Tech Arrangement. Prescribing the recommended BVB medicines reduces the financial burden on the HSE arising out of the funding of reimbursed medicines, and can assist in facilitating access to new, innovative medicine for patients.
The MMP recommends that all new patients being initiated on treatment with filgrastim on the High Tech Arrangement should be prescribed a BVB medicine.
NOTE: Please see the communication entitled MMP Communication - BVB Medicines Filgrastim 27 March 2025 below for information on the current availability of BVB medicines. At this point in time, where a clinician chooses to prescribe a BVB medicine for filgrastim for a patient, a prescription for Accofil® should be provided to the patient.
Resources to support prescribing of the BVB medicine are available below.
- MMP Evaluation Report BVB Medicines - Filgrastim (PDF, 888 KB, 35 pages)
- MMP Communication - BVB Medicines Filgrastim 27 March 2025 (PDF, 795 KB, 10 pages)
- BVB Reimbursement of Filgrastim Questions and Answers for Healthcare Professionals (PDF, 584 KB, 5 pages)
- BVB Filgrastim Patient Information (PDF, 502 KB, 3 pages)
- BVB Accofil® Product Information Sheet (PDF, 685 KB, 3 pages)
- BVB Filgrastim Patient and Clinic Support Services (PDF, 436 KB, 1 page)
For further information, please contact mmp@hse.ie.
Teriparatide
Best-value biological medicines: Teriparatide
The Medicines Management Programme (MMP) has identified best-value medicines (BVMs) for medicinal products containing teriparatide.
The MMP recommends the following as BVMs for teriparatide:
- Movymia® (Clonmel Healthcare Limited)
- Sondelbay® (Accord Healthcare Ireland Limited)
- Terrosa® (Gedeon Richter Ireland)
- Tetridar® (Teva Pharmaceuticals Ireland).
The MMP Evaluation Reports are available below.
Clinicians should give due consideration to prescribing Movymia®, Sondelbay®, Terrosa® or Tetridar® when issuing a prescription for teriparatide on the High Tech Arrangement.
The MMP recommends that all new adult patients who are commencing treatment with teriparatide should be prescribed a BVM, i.e. Movymia®, Sondelbay®, Terrosa® or Tetridar®.
From 1 March 2023, reimbursement of teriparatide on the High Tech Arrangement for treatment-naïve individuals (i.e. adults commencing treatment with teriparatide) is only supported for BVMs, as identified by the MMP.
Resources to support prescribing of the BVMs are available below:
- MMP Evaluation Report Best-Value Medicine - Teriparatide (PDF, 588 KB, 29 pages)
- MMP Evaluation Report Best-Value Medicine - Tetridar (PDF, KB, pages)
- MMP Evaluation Report Best-Value Medicine - Terrosa (PDF, 510 KB, 22 pages)
- MMP Communication - Best-Value Medicines Teriparatide 20 February 2023 (PDF, 395 KB, 7 pages)
- MMP Communication - Best-Value Medicines Teriparatide 30 April 2024 (PDF, 266 KB, 2 pages)
- BVM Teriparatide Questions and Answers for Healthcare Professionals (PDF, 379 KB, 9 pages)
- BVM Reimbursement of Teriparatide Q and A for Healthcare Professionals (PDF, 291 KB, 5 pages)
- BVM Teriparatide Patient Information (PDF, 238 KB, 3 pages)
- BVM Movymia® Product Information Sheet (PDF, 418 KB, 4 pages)
- BVM Sondelbay® Product Information Sheet (PDF, 425 KB, 4 pages)
- BVM Terrosa® Product Information Sheet (PDF, 401 KB, 4 pages)
- BVM Tetridar® Product Information Sheet (PDF, 432 KB, 20 pages)
- BVM Teriparatide Patient and Clinic Support Services (PDF, 283 KB, 3 pages)
For further information, please contact mmp@hse.ie.
Tocilizumab
Best-value biological medicines: Tocilizumab
The Medicines Management Programme (MMP) has identified best-value biological (BVB) medicines for medicinal products containing tocilizumab on the High Tech Arrangement.
The MMP recommends the following as BVB medicines for tocilizumab on the High Tech Arrangement:
- Avtozma® (Celltrion Healthcare Ireland Limited)
- Tyenne® (Fresenius Kabi Ireland).
The MMP Evaluation Reports are available below.
The MMP recommends that:
- all new patients being initiated on treatment with tocilizumab on the High Tech Arrangement should be prescribed a BVB medicine
- patients currently established on treatment with tocilizumab on the High Tech Arrangement should be considered for switching to a BVB medicine at the earliest possible opportunity.
From 1 July 2026, reimbursement of tocilizumab on the High Tech Arrangement for treatment-naïve individuals (i.e. individuals commencing treatment with ustekinumab) is only supported for BVB medicines, as identified by the MMP. Further details are available in the letter MMP Communication – BVB Medicines Tocilizumab 24 June 2026, which can be accessed at the link below.
Resources to support prescribing of the BVB medicine are available below:
- MMP Evaluation Report BVB Medicines - Tocilizumab (PDF, 908 KB, 35 pages)
- MMP Evaluation Report BVB Medicine - Avtozma (PDF, 472 KB, 24 pages)
- MMP Communication - BVB Medicines Tocilizumab 19 December 2025 (PDF, 952 KB, 14 pages)
- MMP Communication – BVB Medicine Tocilizumab 27 May 2026 (PDF, 279 KB, 3 pages)
- MMP Communication – BVB Medicine Tocilizumab 24 June 2026 (PDF, 440 KB, 11 pages)
- BVB Tocilizumab Questions & Answers for Healthcare Professionals (PDF, 349 KB, 9 pages)
- BVB Reimbursement of Tocilizumab Q and A for Healthcare Professionals (PDF, 293 KB, 6 pages)
- BVB Tocilizumab Patient Information (PDF, 208 KB, 3 pages)
- BVB Avtozma Product Information Sheet (PDF, 509 KB, 6 pages)
- BVB Tyenne Product Information Sheet (PDF, 713 KB, 6 pages)
- BVB Tocilizumab Patient and Clinic Support Services (PDF, 231 KB, 2 pages)
- BVB Medicine Tocilizumab Switching Letter Template (Word, 76 KB, 2 pages)
For further information, please contact mmp@hse.ie.
Ustekinumab
Best-value biological medicines: Ustekinumab
The Medicines Management Programme (MMP) has identified best-value biological (BVB) medicines for medicinal products containing ustekinumab.
The MMP recommends the following as BVB medicines for ustekinumab:
- Imuldosa® (Accord Healthcare Ireland Limited)
- Otulfi® (Fresenius Kabi Ireland)
- Pyzchiva® (Sandoz Limited trading as Rowex)
- Uzpruvo® (Clonmel Healthcare Limited)
- Wezenla® (Amgen Ireland Limited).
The MMP Evaluation Reports are available below.
Clinicians should give due consideration to prescribing Imuldosa®, Otulfi®, Pyzchiva®, Uzpruvo® or Wezenla® when issuing a prescription for ustekinumab for the treatment of plaque psoriasis, psoriatic arthritis or Crohn’s disease.
The MMP recommends that:
- all new patients being initiated on ustekinumab for the treatment of plaque psoriasis, psoriatic arthritis or Crohn’s disease should be prescribed a BVB medicine
- patients currently established on ustekinumab for the treatment of plaque psoriasis, psoriatic arthritis or Crohn’s disease should be considered for switching to a BVB medicine at the earliest possible opportunity.
From 1 July 2026, reimbursement of ustekinumab on the High Tech Arrangement for treatment-naïve individuals (i.e. individuals commencing treatment with ustekinumab) is only supported for BVB medicines, as identified by the MMP. Further details are available in the letter MMP Communication – BVB Medicines Ustekinumab 24 June 2026, which can be accessed at the link below.
Resources to support prescribing of the BVB medicine are available below:
- MMP Evaluation Report BVB Medicines - Ustekinumab (PDF, 1,116 KB, 66 pages)
- MMP Evaluation Report BVB Medicine - Uzpruvo (PDF, 572 KB, 38 pages)
- MMP Communication - BVB Medicines Ustekinumab 19 December 2025 (PDF, 952 KB, 14 pages)
- MMP Communication - BVB Medicines Ustekinumab 12 June 2026 (PDF, 289 KB, 3 pages)
- MMP Communication – BVB Medicines Ustekinumab 24 June 2026 (PDF, 455 KB, 14 pages)
- BVB Ustekinumab Questions & Answers for Healthcare Professionals (PDF, 371 KB, 11 pages)
- BVB Reimbursement of Ustekinumab Q and A for Healthcare Professionals (PDF, 299 KB, 8 pages)
- BVB Ustekinumab Patient Information (PDF, 210 KB, 4 pages)
- BVB Imuldosa® Product Information Sheet (PDF, 763 KB, 4 pages)
- BVB Otulfi® Product Information Sheet PDF, 695 KB, 4 pages)
- BVB Pyzchiva® Product Information Sheet (PDF, 833 KB, 8 pages)
- BVB Uzpruvo® Product Information Sheet (PDF, 437 KB, 5 pages)
- BVB Wezenla® Product Information Sheet (PDF, 1 MB, 9 pages)
- BVB Ustekinumab Patient and Clinic Support Services (PDF, 490 KB, 4 pages)
- BVB Medicine Ustekinumab Switching Letter Template (Word, 75 KB, 1 page)
For further information, please contact mmp@hse.ie.
BVB/BVM Processes 2026
Information in relation to potential best-value biological (BVB) medicine and best-value medicine (BVM) processes for 2026.
MMP BVB and BVM Processes 2026 (PDF, 449 KB, 1 page)
The MMP is undertaking a BVB medicine evaluation process for medicinal products containing denosumab 60 mg. Further information is available at the link below.